Medication info
Hyduang Duo Extended-Release Tablet 12.5/1000 mg (Empagliflozin, Metformin)

Hyduang Duo Extended-Release Tablet 12.5/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Brown, double-convex, oval-shaped, extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501632 · Approved 2025.07.01 · Insurance code 670609570

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Increase the dose of metformin hydrochloride gradually to reduce gastrointestinal adverse reactions associated with metformin use. Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is adequately controlled (refer to Precautions for Use, 5. General Precautions). For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose is empagliflozin 10 mg together with the patient's current dose of metformin. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant treatment with empagliflozin and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. (Refer to Precautions for Use, 4. Adverse Reactions and 6. Interactions.) Special populations Renal impairment As dose adjustment according to renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], if the medicine is well tolerated and there are no other conditions that may increase the risk of lactic acidosis, it may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medicine must be discontinued immediately. Elderly patients Patients 75 years of age and older: Consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Uncontrolled blood sugar in type 2 diabetes
  • cardiovascular disease
  • cardiovascular events
View approved original text

This medication is used in conjunction with diet and exercise therapy to help control blood sugar levels in adult patients with type 2 diabetes. It is particularly effective for patients whose blood sugar is not adequately controlled, and precautions should be considered for patients with concurrent cardiovascular disease. This medication improves blood sugar control and aids in the management of type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Increase the dose of metformin hydrochloride gradually to reduce gastrointestinal adverse reactions associated with metformin use. Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is adequately controlled (refer to Precautions for Use, 5. General Precautions). For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose is empagliflozin 10 mg together with the patient's current dose of metformin. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant treatment with empagliflozin and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. (Refer to Precautions for Use, 4. Adverse Reactions and 6. Interactions.) Special populations Renal impairment As dose adjustment according to renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], if the medicine is well tolerated and there are no other conditions that may increase the risk of lactic acidosis, it may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medicine must be discontinued immediately. Elderly patients Patients 75 years of age and older: Consider renal function and the risk of volume depletion.

Precautions

This medication is used to treat diabetes and helps lower blood sugar. However, there are some precautions that must be strictly followed while taking this medication. First, this medication can occasionally cause a rare and serious condition called lactic acidosis. Lactic acidosis is a severe problem caused by the accumulation of lactic acid in the body, with symptoms that may include fatigue, muscle pain, difficulty breathing, and abdominal pain. If any of these symptoms occur, consult a doctor immediately. Second, caution should be exercised when using this medication in combination with other diabetes medications such as insulin or sulfonylureas, as there is a risk of hypoglycemia. Symptoms of hypoglycemia include dizziness, trembling, and cold sweats; rapid action is needed if these symptoms occur. Third, this medication should not be used in patients with renal impairment, acute kidney problems, severe infections, heart failure, myocardial infarction, or other serious health conditions. Additionally, if undergoing a radiographic contrast examination, it is advised to discontinue this medication for a certain period before and after the examination. Fourth, this medication should be used cautiously in patients with dehydration, severe vomiting or diarrhea, malnutrition, liver dysfunction, or excessive alcohol consumption. Elderly patients or those at risk of fluid loss should pay close attention to their fluid status during treatment. Fifth, this medication can cause genital and urinary tract infections, so treatment should be sought immediately if infection symptoms appear. It may also cause vitamin B12 deficiency, so regular monitoring of vitamin levels is recommended during prolonged use. Sixth, pregnant women or women of childbearing potential should not take this medication, and breastfeeding mothers are advised to stop breastfeeding. Seventh, this medication should be swallowed whole without crushing or chewing the tablets, and while the tablet shell may appear in the stool, this is normal. Finally, alcohol consumption should be avoided while taking this medication, and if used in combination with other medications, interactions may occur, so it is essential to consult a doctor or pharmacist.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased vitamin B12 and deficiency
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
Show 162 more
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • vulvar molinaria
  • vulvitis
  • balanitic inflammation
  • perineal necrosis
  • decreased blood sugar
  • hypotension
  • dehydration
  • low blood pressure
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colonic hemorrhage
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • ovarian-tubal abscess
  • vestibular neuritis
  • acute pyelonephritis
  • headache
  • cerebral aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • ureterolithiasis
  • acute kidney injury
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • ureteral pain
  • abnormal urination
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dizziness
  • insomnia
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal crystal formation
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • epistaxis
  • allergic rhinitis
  • skin laceration
  • rib fracture
  • iliotibial band syndrome
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. It is best to maintain storage temperatures within a range of 1 to 30 degrees Celsius to safely preserve the medication's effectiveness for a long time.

Appearance and packaging

Appearance

Brown, double-convex, oval-shaped, extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.